20042020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My research interests encompass various aspects of translational medicine and in particular molecular mechanisms of chemotherapy resistance, identification of disease molecular signature and personalized (or precision) genotype targeted therapy for acute myeloid, lymphoblastic and mixed lineage leukaemia.

My current projects focus on cell signaling in Mixed Lineage Leukemia (MLL) with the aim to understand the mechanisms of chemotherapy resistance underpinning this aggressive leukemia and to design novel molecular targeted therapeutic approaches exploiting the concept on “oncogene addiction”, that means understanding and targeting the oncogenic survival pathway.

 

Formerly trained in gene and stem cell therapy, after completing my Master’s studies I enrolled the PhD program of the European School of Molecular Medicine, focused on cancer and human genetics. There I characterized a rare population of stem cells within the mouse bone marrow, the mesenchymal stromal cells (BMSCs), investigating their self-renewal, differentiation and tumourigenic potential. To pursue my interest in the biology of stem cells and the molecular events underlying their transformation in cancer stem cells, I then joined as post-doc the team of Prof. Eric So at the Institute of Cancer Research, and eventually moved to King’s College London  in 2010 when the group transferred there. At King’s I studied the molecular pathways required for establishment and maintenance of Mixed Lineage Leukaemia (MLL) stem cells, contributing to validate Beta Catenin as a new therapeutic target for MLL through genetic (Knock out mice) and functional (shRNA) approaches. Building on these skills I established my own research domain within the team, developing a therapy-oriented research project working on how to exploit DNA damage repair defects to target leukemic stem cells while sparing the normal ones, an exciting and emerging field in leukaemia therapeutics. This work led to a patent filed in the UK in 2014 and a manuscript published in Nature Medicine in 2015. I have been awarded in 2017 the John Goldman fellowship to investigate mechanisms of chemotherapy resistance in MLL.

 

My technical expertise spans from cellular and molecular biology techniques to histology, microscopy and flow cytometry. Expert in isolation of stem cells from bone marrow, in vitro cell culture, differentiation assays, proliferation assays, gene cloning, adenoviral and lentiviral vector preparations, RNAi technologies, nucleic acids isolation, qPCR, biochemistry, and techniques to study DNA damage repair.

 

Biography

- Senior Lecturer in Biomedical Science (Cancer Biology) Department of Life Sciences University of Roehampton (from October 2017)

- Lecturer Biomedical Science (Cancer Biology) School of Health, Sport and Bioscience University of East London (November 2015-September 2017)

 - Visiting Lecturer Biomedical Science Department of Life Sciences, University of Roehampton  (October 2015)

- Post-doctoral Research Associate Department of Haematological Medicine King’s College London (January 2010- August 2015)

- Post-doctoral Researcher Department of Haemato-Oncology Institute of Cancer Research  Sutton (September-December 2009)

- Visiting PhD student Kennedy Institute of Rheumatology, Imperial College London (September 2008-March 2009)

- Intern Research Assistant at Department of Biochemistry and Biotechnological Science CEINGE Biotecnologie Avanzate Napoli, Italy (October 2001-February 2005)

Qualifications

- 2016-2017 Postgraduate certification in Teaching and Learning in Higher Education University of East London. Passed with distinction.

- 2005-2009 PhD Molecular Medicine, SEMM European School of Molecular Medicine, CEINGE Biotecnologie Avanzate Napoli, Italy. Passed with no corrections.

- 1999-2004 Five- year Bachelor + Master’s degree in Biotechnological Science with a Major in Medicine, University of Napoli Federico II, Italy. First Class.

Professional affiliations

- Fellow of the Higher Education Academy since 2017

- Member of the British Society of Haematology since 2016

- Member of the European hameatology Association since 2016

- Fellow of the Institute of Biomedical Science since 2016

- Member of the Royal Society of Biology since 2016

- Member and ambassador of the European Association of Cancer Research since 2015

- Member of Association of Italian Scientists in UK since 2015

- Co-founder member of Airicerca since 2014

 

Teaching

 

At the University of Roehampton I contribute to Cell biology, Professional Practice in Biomedical Science, Biomedical Science Clinical Methods, Research Methods (BSc in Biomedical Science) and Cells and disease (Mres in Biomedicine).

 
In the past I contributed to Cell Biochemsitry, Clinical Biochemistry, Haematology and Cell Pathology, Biology of Disease, Clinical Diagnosis (BSc Biomedical Science), Advanced techniques in bioscience and Clinical Diagnosis and Biology of diseases (MSc in Biomedical Science).
 
I supervise BSc, MSc and MRes lab based projects.

 

External positions

Member of the Communications Committee, British Society of Hematology

20 Mar 2017 → …

Keywords

  • Q Science (General)
  • cancer biology
  • leukemia
  • gene therapy

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Open Access
File
6 Downloads (Pure)

Imatinib, the magic bullet for treatment of blood cancer

Esposito, M. T., 26 Feb 2020, In : Frontiers for young minds.

Research output: Contribution to journalArticle

Open Access

Targeting SET‐PP2A complex as a new avenue of treatment for Mixed Lineage Leukemia (MLL) treatment

Di Mambro, A., Arroyo, Y., Calle, Y., Wrench, B., Gribben, J. & Esposito, M. T., 27 Apr 2020, In : British Journal of Haematology. 189, S1, p. 51 52 p.

Research output: Contribution to journalMeeting Abstract

Open Access

POST-TRANSLATIONAL MODIFICATIONS OF PROTEIN PHOSPHATASE 2A (PP2A) IN MIXED LINEAGE LEUKEMIA (MLL)

Arroyo, Y., Di Mambro, A., Calle-Patino, Y., Wrench, B., Gribben, J. & Esposito, M., 30 Apr 2019, (Accepted/In press) HemaSphere. Wolter Kluwer Health, Inc, Vol. 3. p. 450 1 p.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Open Access

TARGETING SET-PP2A INTERACTION AS A NOVEL THERAPEUTIC APPROACH FOR MIXED LINEAGE LEUKEMIA (MLL)

Di Mambro, A., Arroyo, Y., Calle-Patino, Y., Wrench, B., Gribben, J. & Esposito, M., 1 Jun 2019, HemaSphere. HemaSphere: Wolter Kluwer Health, Inc, Vol. 3. p. 72-73 2 p.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Open Access

Prizes

John Goldman fellowship

Maria Teresa Esposito (Recipient), May 2017

Prize: Fellowship awarded competitively

Public Engagement Award University Federico II of Napoli Italy

Maria Teresa Esposito (Recipient), Nov 2007

Prize: Prize (including medals and awards)

Travel Fellowship Consorzio Inter-universitario Biotecnologie, CIB Italy

Maria Teresa Esposito (Recipient), Jul 2009

Prize: Prize (including medals and awards)

Activities

  • 5 Media article or participation
  • 2 Editorial Activity
  • 2 Invited talk

Writer The Conversation

Maria Teresa Esposito (Contributor)

Aug 2017 → …

Activity: Public engagement and outreachMedia article or participation

Oncotarget (Journal)

Maria Teresa Esposito (Referee)

2017 → …

Activity: Publication peer-review and editorial workEditorial Activity

Haematology (Journal)

Maria Teresa Esposito (Referee)

2016 → …

Activity: Publication peer-review and editorial workEditorial Activity

News Editor Airicerca

Maria Teresa Esposito (Organiser)

Mar 2014Sep 2017

Activity: Public engagement and outreachMedia article or participation